$1.30
4.00% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US17322U2078
Symbol
CTXR

Citius Pharmaceuticals Inc Stock price

$1.30
-0.37 22.16% 1M
-1.32 50.38% 6M
-2.70 67.50% YTD
-15.98 92.48% 1Y
-27.95 95.56% 3Y
-24.45 94.95% 5Y
-636.20 99.80% 10Y
-373.70 99.65% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.05 4.00%
ISIN
US17322U2078
Symbol
CTXR
Industry

Key metrics

Basic
Market capitalization
$14.0m
Enterprise Value
$13.9m
Net debt
positive
Cash
$30.0k
Shares outstanding
8.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 0.9
EV/Sales
- | 0.9
EV/FCF
negative
P/B
0.2
Financial Health
Equity Ratio
60.1%
Return on Equity
-57.4%
ROCE
-60.0%
ROIC
-52.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $16.0m
EBITDA
$-42.7m | -
EBIT
$-43.0m | $-29.5m
Net Income
$-43.1m | $-29.1m
Free Cash Flow
$-23.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-9.1% | -
EBIT
-9.9% | 29.8%
Net Income
-15.4% | 27.5%
Free Cash Flow
22.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -182.2%
Free Cash Flow
-
More
EPS
$-5.0
FCF per Share
$-2.7
Short interest
10.5%
Employees
23
Rev per Employee
$0.0
Show more

Is Citius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Citius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Citius Pharmaceuticals Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Citius Pharmaceuticals Inc forecast:

Buy
78%
Hold
22%

Financial data from Citius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
20% 20%
-
- Research and Development Expense 12 12
10% 10%
-
-43 -43
9% 9%
-
- Depreciation and Amortization 0.32 0.32
-
-
EBIT (Operating Income) EBIT -43 -43
10% 10%
-
Net Profit -43 -43
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Citius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Citius Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
about 2 hours ago
$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction CRANFORD, N.J. , Aug. 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to t...
Neutral
PRNewsWire
26 days ago
CRANFORD, N.J. , July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering pr...
Neutral
PRNewsWire
27 days ago
CRANFORD, N.J. , July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering pr...
More Citius Pharmaceuticals Inc News

Company Profile

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Head office United States
CEO Leonard Mazur
Employees 23
Founded 2007
Website www.citiuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today